Profile
Samuel Hopkins worked as the Chief Scientific Officer at SCYNEXIS, Inc. and as the President of Research & Development at Parion Sciences, Inc. Prior to that, he was the Senior Vice President of Medical Affairs at Trimeris, Inc. Hopkins received his doctorate from the Medical College of Virginia in 1985 and his undergraduate degree from Western University of Health Sciences in 1980.
Former positions of Samuel Hopkins
| Companies | Position | End |
|---|---|---|
Trimeris, Inc.
 Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | Chief Tech/Sci/R&D Officer | 2000-12-31 |
Parion Sciences, Inc.
 Parion Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Parion Sciences operates as a development-stage pharmaceutical company focused on the discovery and development of new treatments for serious diseases in multiple therapeutic areas. The firm's technology corrects defects in the innate defense of mucosal surfaces by developing inhibitors of the epithelial sodium channel (ENaC). The company was founded by Richard C. Boucher and is headquartered in Durham, NC. | Chief Tech/Sci/R&D Officer | - |
| SCYNEXIS, INC. | Chief Tech/Sci/R&D Officer | - |
Training of Samuel Hopkins
| Western University of Health Sciences | Undergraduate Degree |
| Medical College of Virginia | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| SCYNEXIS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Parion Sciences, Inc.
Parion Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Parion Sciences operates as a development-stage pharmaceutical company focused on the discovery and development of new treatments for serious diseases in multiple therapeutic areas. The firm's technology corrects defects in the innate defense of mucosal surfaces by developing inhibitors of the epithelial sodium channel (ENaC). The company was founded by Richard C. Boucher and is headquartered in Durham, NC. | Commercial Services |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | Health Technology |
- Stock Market
- Insiders
- Samuel Hopkins
